RxDoctor Payments Data

Huy Duong, DO

Pulmonary Disease · Fort Worth, TXNPI 1023003639

Payments from drug & device makers

$2,238in general payments, 2019–2025

Across 103 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$317
  • Mylan Specialty L.p.$284
  • Regeneron Healthcare Solutions, Inc.$160
  • GSK$155
  • Insmed, Inc.$144
  • Boehringer Ingelheim$135
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,15996%
  • Education$794%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,238 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$158,356
Medicare patients
488
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate33$328,950
Trelegy ElliptaFluticasone/Umeclidin/Vilanter150$152,789
ZemairaAlpha-1-Proteinase Inhibitor12$99,582
XolairOmalizumab19$66,910
Breo ElliptaFluticasone/Vilanterol68$42,586
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$30,698
SymbicortBudesonide/Formoterol Fumarate39$16,297
EliquisApixaban18$16,218
Arnuity ElliptaFluticasone Furoate31$12,340
XareltoRivaroxaban12$6,308
BreynaBudesonide/Formoterol Fumarate14$4,182
Albuterol Sulfate HfaAlbuterol Sulfate124$4,064
Wixela InhubFluticasone Propion/Salmeterol15$2,158
Ventolin HfaAlbuterol Sulfate11$1,630
Montelukast Sodium55$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$135$328,95033 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$155$207,715249 claims
AstraZenecaBreztri Aerosphere, Symbicort$317$46,99460 claims
PfizerEliquis$31$16,21818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →